New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MYL;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 8, 2015
15:27 EDTMYLMylan hasn't made compelling case for Perrigo adding value, says BMO Capital
Subscribe for More Information
15:16 EDTMYLPerrigo not likely interested in a Mylan deal, says BMO Capital
14:23 EDTMYLAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
13:07 EDTMYLMylan bid for Perrigo makes strategic sense, says JPMorgan
Subscribe for More Information
13:03 EDTMYLPerrigo says board will meet to discuss Mylan proposal
Subscribe for More Information
12:17 EDTMYLOn The Fly: Midday Wrap
Subscribe for More Information
11:51 EDTMYLPerrigo calls active on Mylan proposal to acquire for $205 per share
Subscribe for More Information
11:45 EDTMYLMylan volatility up after proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:40 EDTMYLPerrigo up $47.10 to $211.81, trading above Mylan's $205/share proposal
Subscribe for More Information
11:35 EDTMYLGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
Subscribe for More Information
11:34 EDTMYLGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
11:32 EDTMYLMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:31 EDTMYLPerrigo halted for volatility after jumping 7% to $176.42
Subscribe for More Information
11:29 EDTMYLMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:16 EDTMYLMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
April 7, 2015
10:19 EDTMYLHigh option volume stocks
Subscribe for More Information
07:32 EDTMYLMylan launches Norethindrone and Ethinyl Estradiol Tablets in U.S.
Subscribe for More Information
07:14 EDTMRKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use